Fibromyalgia – The possibilities of treating chronic and chronic-recurrent pain syndrome with biological immunopharmaceuticals

Germany, Geisenheim, February 2009 – A group of renowned pain therapists and immunologists have established that a treatment with LACTOBIN® N leads to a significant pain abatement in up to 40% of patients with Fibromyalgia or chronic-recurrent pain syndromes. In some the effect was a complete pain relief.

This was the result of the clinical testing of LACTOBIN® N or bioequivalent preparations with several hundred fibromyalgia patients. Several years of research about the causes of the fibromyalgia syndrome led to new findings about the mechanism of LACTOBIN® N at the end of last year.

A new publication about the pathomechanism of fibromyalgia is to be published in the coming months and may open up a new way of therapy for patients with fibromyalgia syndrome.

The therapeutic effect of the oral immunoglobulin preparation LACTOBIN® N starts after 4 to 10 days. The only known contra indication Lactobin® N is lactose intolerance or sensitization to milk proteins.

Read the article by Prof. Sprotte, Director of the Pain Centre of the University Wurzburg, Germany published in the journal, Optimist 03/2008.

Further information:
Email: info@lactobin.de
Phone: + 49 6722 5610 0

(Click here to read the complete article including literature references - http://www.lactobin.de/en/artikel.php)

Title: The possibilities of treating chronic and chronic-recurrent pain syndrome with biological immunopharmaceuticals (syn.: biologics)

Summary

The extent of pain, exhaustion and functional disorders from which humans with fibromyalgia suffer can hardly be conveyed to most people and the physicians who are asked for help. For the persons concerned, the fact that medical science has so far found only a few concepts regarding a meaningful diagnosis and therapy, which corresponds only partly to the expectations of most patients, is particularly discouraging.
Nevertheless, in the meantime it has been shown in a large group of patients with fibromyalgia and to some extent also with other pain syndromes, that a pathological increased permeability of the intestinal mucosa exists (Disturbance of the physiological mucous membrane barrier of the small intestine).
The order of magnitude of this deterioration corresponds to that also found in patients with chronic inflammatory intestinal illnesses. Chronic pain in addition to that in the intestinal region is also very common with these patients, the fibromyalgia syndrome alone accounting for over 30%.
However, a respective local inflammation reaction in the intestine which is reflected in the blood values is missing with primary fibromyalgia. The only clinical reference to participation of the intestine in this complex health problem with many patients is a simultaneous so-called irritable bowel syndrome.
On the long road to scientific clarification of this strange barrier disturbance, which is not accompanied by any substantial inflammatory reaction, it was possible to achieve important partial results. Hidden immune reactions, which will perhaps prove a crucial key to the biological understanding of the entire disease complex, were discovered. Strategies could also already be tested, which permit an important part of the problem to be neutralized with natural biological weapons. These weapons are e.g. the antibodies of the immune system. They can also be obtained for this purpose from animal sources and supplemented as dietetic foodstuffs in the intestine. The first standardized preparation has been obtained from cows' foremilk, the high protein content of which essentially consists of antibodies. The preparation is available under the commercial name LACTOBIN® N.

The scientific way to new findings and the first therapeutical successes with biologics in chronic pain

Possible causes of chronic pain have been researched at the pain centre of the University Hospital Wurzburg for more than 20 years, whereby an immunological major research focus existed from the outset. Scientists from several sub-areas of biomedicine from the University of Wurzburg, the Charité in Berlin and later on also from the USA (Harvard) and Great Britain (Oxford and London) were involved in the project.

(Click here to read the complete article including literature references - http://www.lactobin.de/en/artikel.php)

Dr. Wolz Zell GmbH was founded in 1969 by Siegfried Wolz in Geisenheim and specialises in the development of functional food supplements on the basis of cellular respiration.
Dr. Wolz Zell GmbH manufactures only products with ingredients that have been scientifically researched and which have proven effects. All products are manufactured in a demanding process, taking particular care to ensure good bioavailability of the biological substances. During the last 2 years a new cooperation with clinical pharmacologists and immunologists has occurred with the developement of Dr. Wolz Zell GmbH was founded in 1969 by Siegfried Wolz in Geisenheim and specialises in the development of functional food supplements on the basis of cellular respiration.
Dr. Wolz Zell GmbH manufactures only products with ingredients that have been scientifically researched and which have proven effects. All the products contain natural, biological ingredients which are derived exclusively from natural sources. They are manufactured in a demanding process, taking particular care to ensure good bioavailability of the biological substances. During the last 2 years a new cooperation with clinical pharmacologists and immunologists has occurred with the developement of LACTOBIN® N.

Dr. Wolz Zell GmbH
Buchenweg 9
D-65366 Geisenheim
Germany

http://www.lactobin.de/en

Contact:
Tel: + 49 6722 - 5610 - 0
Fax: +49 6722 - 5610 - 20
E-Mail: info@lactobin.de

This release was published on openPR.